000143033 001__ 143033
000143033 005__ 20240229112540.0
000143033 0247_ $$2doi$$a10.1177/1534735419832358
000143033 0247_ $$2pmid$$apmid:30795696
000143033 0247_ $$2ISSN$$a1534-7354
000143033 0247_ $$2ISSN$$a1552-695X
000143033 0247_ $$2altmetric$$aaltmetric:55997470
000143033 037__ $$aDKFZ-2019-00652
000143033 041__ $$aeng
000143033 082__ $$a610
000143033 1001_ $$aBühl, Linda$$b0
000143033 245__ $$aFeasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report.
000143033 260__ $$aThousand Oaks, Calif.$$bSage$$c2019
000143033 3367_ $$2DRIVER$$aarticle
000143033 3367_ $$2DataCite$$aOutput Types/Journal article
000143033 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1552295628_23195
000143033 3367_ $$2BibTeX$$aARTICLE
000143033 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143033 3367_ $$00$$2EndNote$$aJournal Article
000143033 520__ $$aIn patients with hematological malignancies, exercise is studied as a supportive measure with potential benefits on therapy and disease-related side effects. However, clinical trials have not yet integrated people with Down syndrome (DS), although this disability is associated with an increased risk for hematological malignancies. Therefore, we examined safety and feasibility of a mixed-modality exercise intervention in a male with DS undergoing high-dose chemotherapy for acute lymphoblastic leukemia. Furthermore, physical capacity and fatigue were assessed. Exercise sessions took place 3 times/wk over a 5-week period. Adherence to the exercise program was 100%, and no serious adverse events occurred. In contrast to the training sessions, applied endurance testing was not feasible. Furthermore, maintenance of fatigue level was observed. In conclusion, cancer patients with DS suffering from leukemia should not be excluded from physical activity or exercise programs.
000143033 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143033 588__ $$aDataset connected to CrossRef, PubMed,
000143033 7001_ $$aAbel, Thomas$$b1
000143033 7001_ $$aWolf, Florian$$b2
000143033 7001_ $$aOberste, Max$$b3
000143033 7001_ $$aBloch, Wilhelm$$b4
000143033 7001_ $$aHallek, Michael$$b5
000143033 7001_ $$aElter, Thomas$$b6
000143033 7001_ $$0P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aZimmer, Philipp$$b7$$eLast author$$udkfz
000143033 773__ $$0PERI:(DE-600)2101248-9$$a10.1177/1534735419832358$$gVol. 18, p. 153473541983235 -$$p153473541983235 -$$tIntegrative cancer therapies$$v18$$x1552-695X$$y2019
000143033 909CO $$ooai:inrepo02.dkfz.de:143033$$pVDB
000143033 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143033 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143033 9141_ $$y2019
000143033 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000143033 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143033 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINTEGR CANCER THER : 2017
000143033 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143033 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143033 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143033 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143033 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143033 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143033 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ
000143033 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143033 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143033 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143033 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143033 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000143033 980__ $$ajournal
000143033 980__ $$aVDB
000143033 980__ $$aI:(DE-He78)C110-20160331
000143033 980__ $$aUNRESTRICTED